Letrozole

Letrozole is a prescription tablet in a drug class called aromatase inhibitors, which block one of the enzymes the body uses to make estrogen. In the United States, its approved use is breast cancer: hormone receptor positive breast cancer in women who have already gone through menopause. It is also used widely, and off label, to trigger ovulation in people trying to conceive. Those two lives explain why search results for this drug look split down the middle, and this page keeps them separate.

It is a prescription-only medicine taken by mouth, not an over-the-counter supplement and not a hormone you add to the body. It does the opposite: it lowers estrogen. That single fact drives almost everything else on this page, from the joint aches people report to the reason fertility clinicians reach for it. If you are cross-checking several drugs at once, the Medication Guide Index covers the rest of the compounds tracked on this site.

What letrozole is and who takes it

Two very different groups take this tablet. The first is people treated for early or advanced hormone receptor positive breast cancer after menopause. There, it is endocrine therapy, sometimes called hormone therapy, and it is usually taken daily for years rather than weeks. It is not chemotherapy and does not work the way chemotherapy does.

The second group is people with ovulation problems who are trying to get pregnant. There, it is given in short courses early in the menstrual cycle, under monitoring, and it is off label in the US. Off label means a clinician may legally prescribe it for that purpose, but the FDA has not reviewed that use, so the official labeling carries no fertility dosing, no fertility safety section and no fertility efficacy data.

A third group shows up in search data: men. Off-label use in men exists, mostly around high estradiol, gynecomastia or as an add-on in male fertility care, and it is covered further down. Nothing in the US label supports it.

How it works: switching down estrogen production

Aromatase is the enzyme that converts androgens, including testosterone, into estrogens. After menopause the ovaries largely stop producing estrogen, so most of what remains is made in fat, muscle and skin through that enzyme. Blocking aromatase drops circulating estrogen sharply. For a tumor whose cells grow in response to estrogen, that removes the growth signal, which is the point of the treatment. The manufacturer labeling and the FDA prescribing information describe this mechanism in detail; you can read the current label text through the National Library of Medicine DailyMed label archive.

In someone who still ovulates, the same effect produces a different result. Lower estrogen means the brain senses a shortage and raises follicle stimulating hormone. More FSH pushes follicles in the ovary to grow, and ovulation can follow. The drug also clears the body relatively quickly, with a half-life measured in days rather than weeks, which is one reason fertility specialists favor it over older options that linger through the cycle. A National Institutes of Health review of the fertility literature walks through this mechanism and its clinical use in female infertility.

Worth naming the trade-off up front: low estrogen is the therapy and also the source of most side effects. Hot flashes, joint stiffness and bone thinning are not random. They are what a low-estrogen state feels like.

Approved breast cancer uses

The US label covers three situations, all in postmenopausal women:

• Adjuvant treatment of early breast cancer that is hormone receptor positive, meaning treatment after surgery to lower the chance of recurrence.
• Extended adjuvant treatment for people with early breast cancer who have already completed standard adjuvant tamoxifen therapy.
• First and second line treatment of advanced breast cancer that is hormone receptor positive, or where receptor status is unknown.

The approved product is an oral tablet, and the labeled strength is 2.5 mg taken once daily, with or without food. Duration is a decision for the treating oncology team, not something to adjust at home, and the label is the authority on dosing in specific situations such as liver impairment. Patient-facing background on how the drug fits into breast cancer treatment is available from the National Cancer Institute drug information page.

One nuance often missed: the approved indications are for people who are postmenopausal. In premenopausal patients the ovaries keep making estrogen through a pathway this drug does not fully control, so oncologists who use aromatase inhibitors before menopause pair them with ovarian suppression. That is a specialist decision built on trial evidence, not a self-service option.

Off-label use for ovulation and fertility

This is the reason most people arrive here. In fertility care, the tablet is used to induce ovulation in people who ovulate irregularly or not at all, most often with polycystic ovary syndrome, and sometimes in unexplained infertility. It is paired with timed intercourse or intrauterine insemination, used in some milder IVF stimulation protocols, and used in fertility preservation cycles for people about to start cancer treatment. Large fertility reviews now describe it as a first choice for ovulation induction in PCOS rather than a second-line fallback.

A typical monitored cycle follows a recognizable shape. Steps vary by clinic and none of this is a prescription:

1. Baseline workup: bloodwork, a pregnancy test, and often a baseline ultrasound to check the ovaries and lining.
2. A short course of tablets started on specific cycle days chosen by the prescribing clinician.
3. Follicle monitoring by ultrasound, sometimes with hormone bloodwork, to see how many follicles are growing.
4. Timing: intercourse, insemination, or a trigger injection when the clinician judges the follicle ready.
5. A pregnancy test roughly two weeks later, then a decision about repeating, changing approach, or escalating.

What about results? In the largest US randomized trial in polycystic ovary syndrome, this drug produced more ovulatory cycles and more live births than clomiphene citrate. Success still depends heavily on age, egg reserve, sperm quality, tubal status, weight and how many cycles you complete, so no honest page can quote you a personal chance. The underlying comparative studies are indexed in the PubMed database of published trials.

Two safety questions come up constantly. Multiple pregnancy: any ovulation induction raises the chance of twins, though the risk is generally lower than with injectable gonadotropins. Birth defects: a 2005 conference abstract raised a concern that later, larger datasets have not confirmed, and the drug clears the body well before implantation. Neither point replaces a conversation with a clinician who knows your history.

If you are tracking cycle timing while you plan a monitored cycle, an estimate helps more than guessing.

What about letrozole for men?

Use in men is entirely off label. Small studies have looked at aromatase inhibitors for men with low testosterone and a high estradiol ratio, for gynecomastia, and as part of male fertility protocols. Evidence is limited, dosing is not established in labeling, and the same low-estrogen consequences apply: estrogen matters for male bone density and libido too. Use bought outside a clinical relationship, including alongside anabolic steroids, comes with no monitoring of bone, lipids or hormone levels. If a program offers this pathway, ask what bloodwork it repeats and how long it intends to continue.

How it compares with clomiphene citrate

Neither drug is universally better. Clomiphene remains a reasonable option, particularly where cost, familiarity or prior response favors it. The comparison matters most in PCOS, where the trial data are strongest.

Side effects people report most

The commonly reported effects reflect low estrogen. In breast cancer trials, hot flashes and joint or muscle pain are the two complaints that dominate. Others reported include:

• Night sweats and flushing
• Fatigue, dizziness or drowsiness
• Headache
• Joint stiffness, especially in the morning
• Hair thinning
• Nausea and reduced appetite
• Mood changes and low libido
• Vaginal dryness

Fertility courses last days rather than years, so most people notice milder and shorter-lived effects, often hot flashes, tiredness or headaches that ease after the course ends. Long-term daily use is where the slower risks matter. Labeling flags that bone mineral density may fall, which raises fracture risk over time, and that total cholesterol may rise, so bone density and lipid monitoring are both worth asking about. Background on bone loss and how it is monitored is available from the NIH institute that covers bone and joint conditions.

Less common but more serious: allergic reactions including swelling or rash, changes in liver enzymes, chest pain, unusual vision changes, or severe pelvic pain and rapid abdominal swelling during a stimulated cycle. Those belong in front of a clinician promptly rather than in a forum thread. General patient-level summaries of expected and unexpected effects are maintained by Cleveland Clinic in its plain-language drug reference.

Warnings, pregnancy risk and interactions

The single most important warning is pregnancy. The label states the drug can cause fetal harm, and advises a pregnancy test in people of reproductive potential plus effective contraception during oncology treatment, per the FDA prescribing information available through Drugs@FDA. This is exactly why fertility use is structured the way it is: short courses given before ovulation, with pregnancy ruled out first, in a drug that clears quickly. It is not a contradiction, but it is a reason not to improvise timing at home.

Other label-flagged points, in plain English:

• Bone effects. Bone mineral density may decrease with use, so density monitoring may be considered.
• Cholesterol. Total cholesterol may rise, and lipid monitoring may be considered.
• Fatigue and dizziness. Tiredness, dizziness and drowsiness can occur, so caution with driving and machinery is advised until you know how you respond.
• Hypersensitivity. It should not be used by anyone with a known allergy to the drug.
• Liver function. Reduced liver function affects how the body handles the drug, which the label addresses directly.

Interactions are fewer than with many cancer drugs but real. Taking it with tamoxifen lowers letrozole blood levels substantially, which is why the two are sequenced rather than combined. Estrogen-containing products, including some hormonal contraceptives and menopause hormone therapy, work against the whole purpose of the drug. It is processed by liver enzymes in the CYP family, so strong inhibitors or inducers of those enzymes can shift levels. Bring a full list of prescriptions, over-the-counter products and supplements to the prescribing visit; the NIH-maintained consumer drug references at MedlinePlus drug information are a reasonable place to cross-check.

Femara, generics and the tablet you actually get

Femara is the originator brand name. Letrozole is the generic name, and many manufacturers now market generic versions found through the FDA approval database. Generic tablets approved as therapeutically equivalent are expected to work the same way as the brand, so “letrozole vs Femara” is a packaging and pricing question rather than a clinical one. Tablets from different manufacturers can look different in color, shape and imprint, which unsettles people at refill time; the imprint on the bottle label is the way to confirm.

One practical note about this page: the FDA label section rendered below comes from a single labeler’s submission. If your bottle came from a different manufacturer, the wording may differ slightly while the approved content covers the same ground. A general clinical reference such as the Mayo Clinic oral-route drug monograph is useful for comparison.

What it costs when you are paying cash

Cost is the section most people scroll to, and generic status is the headline fact: this molecule has been off patent for years and is dispensed as a generic tablet by many pharmacies, which usually keeps the cash figure well below brand-only medicines. Prices still move constantly between pharmacies, so treat any figure you see as a snapshot rather than a fixture.

Lowest tracked self-pay price per month across programs in this directory: . Median tracked self-pay price: .

What moves the number you are quoted:

• Brand or generic. The originator brand and the generic sit in different price tiers.
• Quantity dispensed. A 90-day fill and a 30-day fill rarely cost proportionally the same.
• Pharmacy type. Retail chains, independents, mail order and fertility-clinic pharmacies price differently for the same tablet.
• What the program fee buys. A telehealth monthly fee may cover the consult, messaging and refills, with medication billed separately by the pharmacy. Ask which is which before you enroll.
• Everything around the tablet. In fertility care, monitoring ultrasounds, bloodwork and insemination usually dwarf the medication line. In oncology care, the drug sits inside a much larger treatment plan.

If you are budgeting a course rather than a single fill, run the yearly figure instead of estimating it.

On coverage, be careful. Plans commonly treat a generic oncology tablet very differently from fertility services, and infertility benefits vary by employer plan and by state mandate. No page can tell you what your plan does, so verify with your own insurer before you assume anything; policy background on how coverage differs across states is tracked by KFF women’s health policy research. Cash pay and insurance are separate routes here, and this site tracks them separately, since a membership fee tells you nothing about your copay. The Free Savings Report shows the format used to compare self-pay figures side by side, and the Scoring Methodology explains which dimensions feed a provider’s score, including value and pricing transparency.

How telehealth programs handle it, and what to ask

Fertility-focused telehealth typically starts with a detailed intake, orders bloodwork, and then decides whether a monitored ovulation induction cycle is appropriate. The friction point is imaging: follicle monitoring needs ultrasound, which means a local clinic or imaging center in most arrangements. Programs also differ on whether a reproductive endocrinologist is involved, how many cycles they will run before escalating, and how they coordinate with a partner’s testing. State telemedicine prescribing and licensure rules also decide who can prescribe to you at all, which is why availability shifts by state.

Breast cancer therapy is a different matter. Daily endocrine therapy belongs with an oncology team that tracks recurrence risk, bone density and lipids. Telehealth can support refills and side-effect check-ins around that care; it does not substitute for it.

Questions worth asking any program before you pay:

• Who prescribes, what are their credentials, and are they licensed in my state?
• Is this use on label or off label here, and what does that change for me?
• What bloodwork and imaging do you require before the first cycle, and who pays for it?
• Is monitoring included in the fee, or billed separately?
• Which pharmacy fills the prescription, and can I use my own?
• How many cycles before you recommend a different approach or an in-person specialist?
• What is the follow-up plan for side effects, and how fast do you respond?
• If I stop, what happens to the membership and any remaining fills?

To compare programs on those specifics rather than on marketing copy, the Telehealth Provider Directory lists what each one offers, the Free Health Calculators handle the arithmetic, and Recent Editorial Coverage tracks how the wider market is shifting.

When to get medical help quickly

Some symptoms should not wait for the next appointment. Seek urgent care for chest pain, sudden shortness of breath, one-sided weakness or slurred speech, sudden vision changes, swelling of the face, lips or throat, a spreading rash, yellowing of the skin or eyes, or severe pelvic pain with rapid abdominal swelling during a stimulated cycle. Fainting, a fall with a suspected fracture, or a bone injury from minor force also deserves prompt attention given the bone effects described in the labeling.

Authoritative sources

• DailyMed prescribing information from the National Library of Medicine
• FDA Drugs@FDA approval